Advertisement

PharmacoEconomics & Outcomes News

, Volume 828, Issue 1, pp 24–24 | Cite as

Palivizumab cost effective for RSV prophylaxis in targeted infants

Clinical study
  • 1 Downloads

Reference

  1. Mac S, et al. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143: No. 5, May 2019. Available from: URL: http://doi.org/10.1542/peds.2018-4064

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations